20
Participants
Start Date
May 9, 2024
Primary Completion Date
December 15, 2028
Study Completion Date
December 15, 2042
Cyclophosphamide
"* Safety Run-in: 375mg/m\^2 daily x 3~* Cohort 1: 375mg/m\^2 daily x 3~* Cohort 2: 375mg/m\^2 daily x 3~* Cohort 3: 375mg/m\^2 daily x 3"
CART-BCMA
"* Safety Run-in: 5 x 10\^7 CAR T cells~* Cohort 1: 1.5 x 10\^8 CAR T cells~* Cohort 2: 1.5 x 10\^8 CAR T cells~* Cohort 3: 5 x 10\^8 CAR T cells"
huCART19
"* Safety Run-in: 5 x 10\^7 CAR T cells~* Cohort 1: 1.5 x 10\^8 CAR T cells~* Cohort 2: 1.5 x 10\^8 CAR T cells~* Cohort 3: 5 x 10\^8 CAR T cells"
Fludarabine
• Cohort 3: 24mg/m\^2 daily x 3
RECRUITING
NYU Langone Health (Site #: 71177), New York
RECRUITING
University of Pennsylvania Medical Center (Site #: 71111), Philadelphia
RECRUITING
Massachusetts General Hospital: Transplantation (Site #: 71107), Boston
University of Pennsylvania Clinical Cell and Vaccine Production Facility (CVPF)
UNKNOWN
National Institute of Allergy and Infectious Diseases (NIAID)
NIH